You just read:

Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

News provided by

Prosonix

Jan 23, 2014, 04:00 ET